CUTX-101 is under clinical development by Cyprium Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CUTX-101’s likelihood of approval (LoA) and phase transition for Menkes Disease (Kinky Hair Disease) took place on 17 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CUTX-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CUTX-101 overview
CUTX-101 (Copper histidinate) is under development for the treatment of Menkes disease. The drug candidate is administered through subcutaneous route. Copper histidine acts as a replacement therapy.
Quick View CUTX-101 LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|